Conversion to Silodosin in Men on Conventional α1-Blockers for Symptomatic Benign Prostatic Hyperplasia
Authors:
- 1 April 2010
- journal article
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 2 (1) , 11-15
Abstract
α1 -blockers have commonly been used as first-line medical therapy for symptomatic benign prostatic hyperplasia (BPH). Recently, a highly selective α1A -adrenoceptor antagonist, silodosin, was developed in Japan. We examined the efficacy and safety of conversion from conventional α1 -blockers to silodosin in men with BPH. Conversion to silodosin was proposed to consecutive patients on conventional α1 -blockers for symptomatic BPH for at least 6 months. The effects of conversion were examined by the International Prostate Symptom Score, quality of life index, overactive bladder symptom score, peak flow rate, residual urine volume, and adverse events at 12 weeks. The efficacy of silodosin was also evaluated by patients' impression. Eighty-one men underwent conversion, for the most part because of dissatisfaction with the efficacy of their current treatment in improving nocturia or weak stream. The International Prostate Symptom Score total score significantly improved from 12.7 ± 5.9 at baseline to 10.6 ± 5.4 at 4 weeks (P < 0.001) and 10.9 ± 5.8 at 12 weeks (P < 0.01). The progress was mostly due to improvement in voiding symptoms, although reduction of storage symptoms was also significant. The quality of life index also significantly decreased with conversion to silodosin. Efficacy as judged by patients' impression was 76% (37/49) at 12 weeks of treatment. None of the overactive bladder symptom score, peak flow rate, and residual urine volume exhibited significant change. No serious adverse events were observed during the study period. Conversion to silodosin may be beneficial in men who are dissatisfied with conventional α1 -blockers for BPH, and be particularly useful in improving voiding symptoms.Keywords
This publication has 18 references indexed in Scilit:
- Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaInternational Journal of Urology, 2008
- Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trialBJU International, 2005
- FUNCTION OF THE LOWER URINARY TRACT IN MICE LACKING α 1d -ADRENOCEPTORJournal of Urology, 2005
- AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment RecommendationsJournal of Urology, 2003
- Tamsulosin: an overviewWorld Journal of Urology, 2002
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- Novel role for α 1 ‐adrenergic receptor subtypes in lower urinary tract symptomsBJU International, 2000
- Quantification and distribution of α1‐adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non‐hypertrophied tissueBritish Journal of Pharmacology, 1996
- Localization of the alpha 1A-Adrenoceptor in the Human ProstateJournal of Urology, 1995
- Pharmacological evidence of distinct oci‐adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral arteryBritish Journal of Pharmacology, 1994